GSK3B and infection: Using the dsRNA marker (Fig. 1a), screening against HCoV-229E and SARS-CoV-2 demonstrated that targeting GSK3β resulted in effective viral control in 31% and 19% of the compounds (≥ 50% infection inhibition), respectively.